Comparative Pharmacology
Head-to-head clinical analysis: CIMZIA versus CYLTEZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIMZIA versus CYLTEZO.
CIMZIA vs CYLTEZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
None Documented
None Documented
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor